GlassScriptPhysician profile
Wadi R Rouel
NPI 1740254713
$3,645.47
in general payments reported to CMS, 2019-2025
27 companies · $910 in 2025
The $910 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $154 · 2021: $505 · 2022: $429 · 2023: $702 · 2024: $726 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,339.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $948.52 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $637.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $284.10 | 2020-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $279.10 | 2019-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $209.13 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.48 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.60 | 2020-2025 | Jardiance, Tradjenta |
| Ironwood Pharmaceuticals, INC | $102.58 | 2023-2024 | Linzess |
| Xeris Pharmaceuticals, INC. | $89.77 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Shield Therapeutics INC | $62.13 | 2025 | |
| Amarin Pharma, INC. | $61.22 | 2021 | |
| Dexcom, INC. | $59.52 | 2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $56.13 | 2020-2021 | |
| Exact Sciences Corporation | $49.35 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $44.19 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $43.13 | 2021 | |
| Novartis Pharmaceuticals Corporation | $40.24 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $37.13 | 2021 | |
| Allergan, INC. | $36.98 | 2020 | |
| Abbott Laboratories | $35.91 | 2022 | |
| Merck Sharp & Dohme LLC | $33.48 | 2019-2022 | |
| Amgen INC. | $29.44 | 2022 | |
| Boston Scientific Corporation | $28.67 | 2025 | Watchman Flx |
| Mannkind Corporation | $22.47 | 2021 | |
| Astellas Pharma US INC | $21.17 | 2025 | Veozah |
| Janssen Pharmaceuticals, INC | $17.32 | 2022 | |
| Dermira, INC. | $12.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wadi Rouel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.